ALK Alutard 5-grasses — Competitive Intelligence Brief

ALK Alutard 5-grasses (ALK Alutard 5-grasses) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulator. Area: Allergy.

phase 2 Immunomodulator CD25 Allergy Small molecule

Target snapshot

ALK Alutard 5-grasses (ALK Alutard 5-grasses) — Lars Olaf Cardell. ALK Alutard 5-grasses is an immunotherapy that targets the CD25 antigen.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ALK Alutard 5-grasses TARGET	ALK Alutard 5-grasses	Lars Olaf Cardell	phase 2	Immunomodulator	CD25
Thymoglobulin (ATG)	Thymoglobulin (ATG)	M.D. Anderson Cancer Center	marketed	Polyclonal antithymocyte globulin (ATG)	Multiple T-cell antigens (CD2, CD3, CD4, CD8, CD11a, CD18, CD25, HLA-DR)
Thymoglobuline Genzyme	Thymoglobuline Genzyme	University Hospital, Basel, Switzerland	marketed	Polyclonal antithymocyte globulin (ATG)	Multiple T-cell surface antigens (CD2, CD3, CD4, CD8, CD11a, CD18, CD25, HLA-DR, and others)
tacrolimus, ATG	tacrolimus, ATG	University Hospital, Toulouse	marketed	Calcineurin inhibitor and polyclonal antithymocyte antibody	Calcineurin (tacrolimus); T-cell surface antigens including CD2, CD3, CD4, CD8, CD25 (ATG)
CHOP-daclizumab	CHOP-daclizumab	King's College Hospital NHS Trust	marketed	Monoclonal antibody (daclizumab component) combined with chemotherapy regimen	CD25 (IL-2 receptor alpha chain)
daclizumab, infliximab	daclizumab, infliximab	University of Iowa	marketed	Monoclonal antibody combination	IL-2 receptor alpha (CD25) and TNF-alpha
ATG Fresenius	ATG Fresenius	University Hospital, Basel, Switzerland	marketed	Polyclonal antithymocyte globulin (ATG)	T-cell surface antigens (CD2, CD3, CD4, CD8, CD25, HLA-DR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulator class)

1. Actavis Mid-Atlantic LLC · 1 drug in this class
2. Active Biotech AB · 1 drug in this class
3. Air Force Military Medical University, China · 1 drug in this class
4. Astellas Pharma Inc · 1 drug in this class
5. Bayer · 1 drug in this class
6. Beijing Children's Hospital · 1 drug in this class
7. Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
8. Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri · 1 drug in this class
9. Chang Gung Memorial Hospital · 1 drug in this class
10. ALK-Abelló A/S · 1 drug in this class